ROSSARI
making you more competitive

October 16, 2025

DCS-CRD **BSE Limited** First Floor, New Trade Wing Rotunda Building, Phiroze Jeejeebhoy Towers Dalal Street, Fort Mumbai 400001 Fax No.2272 3121/2037/2039 Stock Code: 543213	Listing Compliance **National Stock Exchange of India Limited** Exchange Plaza, 5th Floor Plot No. C/1, 'G' Block, Bandra- Kurla Complex Bandra East Mumbai 400051 Fax No.2659 8237/8238 Stock Code: ROSSARI

Dear Sir/Madam,

Subject.: Q2 & H1 FY26 Press Release

Please find enclosed a copy of the Press Release for the quarter and half year ended September 30, 2025.

The same may please be taken on record and suitably disseminated to all concerned.

Thanking you,

Yours Sincerely,
For Rossari Biotech Limited

Parul Gupta
Digitally signed by Parul Gupta
Date: 2025.10.16 16:11:18 +05'30'

ROSSARI BIOTECH LIMITED MUMBAI

Parul Gupta
Head - Company Secretary & Legal
Membership No.: A38895

Encl.: as above

Rossari Biotech Limited

Corporate Office: Rossari House, Golden Oak, LBS Marg, Surya Nagar, Opp. Mahindra Showroom, Vikhroli (West), Mumbai – 400079, Maharashtra, India

Rossari Biotech announces Q2 FY26 results

Q2 FY26

Revenues at Rs. 586.1 Cr, up 18% YoY
EBITDA at Rs. 71.9 Cr, up 9% YoY
PAT at Rs. 36.9 Cr, up 5% YoY

Mumbai, October 15, 2025: Rossari Biotech Limited (Rossari), a Specialty-Chemicals manufacturer providing intelligent and sustainable solutions for customers across industries, has announced its financial results for the quarter ended September 30, 2025.

Consolidated: Q2 FY26 performance overview compared with Q2 FY25

- Revenue from operations grew 18% to Rs. 586.1 crore as compared to Rs. 498.4 crore
- EBITDA improved by 9% to Rs. 71.9 crore from Rs. 65.9 crore
  - EBITDA margin at 12.3% as against 13.2%
- PAT increased by 5% to Rs. 36.9 crore from Rs. 35.3 crore
- EPS (Diluted) stood at Rs. 6.7* as against Rs. 6.4*

Consolidated: H1 FY26 performance overview compared with H1 FY25

- Revenue from operations stood at Rs. 1,129.8 crore as against Rs. 988.0 crore, up 14%
- EBITDA increased by 7% to Rs. 139.7 crore as against Rs. 130.8 crore
  - EBITDA margin at 12.4% as against 13.2%
- PAT higher by 0.4% to Rs. 70.5 crore as against Rs. 70.2 crore
- EPS (Diluted) stood at Rs. 12.7* as against Rs. 12.7*

Note:

1) *All figures, unless mentioned otherwise, are on a consolidated basis*
2) ** EPS not annualized*

Commenting on the performance, in a joint statement, Mr. Edward Menezes, Promoter & Executive Chairman, and Mr. Sunil Chari, Promoter & Managing Director, said

"We delivered healthy revenue growth of 18% YoY in Q2 FY26, led by broad-based volume expansion across our key segments. The HPPC, TSC, and AHN businesses grew by 16%, 21%, and 29% respectively, reflecting the continued strength of our diversified portfolio and the focused execution by our teams.

On the export front, we are proud to have expanded our global operations, with several geographies emerging as key drivers of future growth. We registered a strong performance in our export markets by targeting new customers in both new and existing geographies and increasing our wallet share with our partners. For the quarter, Exports grew by 36% YoY and in H1 it grew by 27%, driven by deeper customer engagement in key international markets. Now exports contribute almost 28% of our overall sales.

While robust volumes supported the top line, profitability remained steady owing to subdued pricing and ongoing investments in seeding new business opportunities. We are confident that as these initiatives begin to contribute to revenues, profitability will improve progressively going forward.

With a diversified product portfolio, agile manufacturing capabilities, new capacity additions and a strong balance sheet, we believe we are well-positioned to capitalize on emerging opportunities and drive healthy growth for the foreseeable future. As a growth-focused Company, we remain committed to innovation, continuously developing tailored solutions that meet the evolving needs of our customers. We are working towards expanding our global footprint through our own manufacturing set up and sales & distribution network overseas. This approach strengthens our confidence in delivering sustainable operational and financial performance while creating long-term value for all our stakeholders."

Key Developments

Update on Capacity Expansion Projects

- The Company successfully commissioned an additional 20,000 MTPA capacity at its Dahej facility during the quarter; total installed capacity now at 1,52,500 MTPA
- Commissioned 15,000 MTPA ethoxylation capacity at Unitop (Phase 1 of 30,000 MTPA plan); current installed capacity at 51,000 MTPA
  - Second phase of the expansion expected to be commissioned by Q3 FY26
  - These additions to support scale-up across high-growth verticals: personal care, agrochemicals, oil & gas, pharma
- The Board has approved an investment of up to USD ~8 million in tranches, in Rossari International Limited Company (RILC), a wholly owned subsidiary incorporated in Saudi Arabia in December 2024
  - The proposed investment will support the evaluation and assessment of expansion plan, which aligns with the Company's strategy to enhance its global presence and strengthen its position in international markets

Note: *Home, Personal Care and Performance Chemicals (HPPC); Textile Specialty Chemicals (TSC); Animal Health and Nutrition (AHN)*

< Ends >

About Rossari Biotech Limited:

Rossari Biotech Limited (Rossari) (BSE: 543213, NSE: ROSSARI), is a Speciality-Chemicals manufacturer providing intelligent and sustainable solutions for customers across industries. Headquartered at Mumbai, India, the Company operates strategically located manufacturing facilities at Silvassa and Dahej. The Company offers tailor-made solutions for Home, Personal Care and Performance chemicals (HPPC), Textile speciality chemicals and Animal Health and Nutrition (AHN). With differentiated product offerings, Rossari caters to an array of applications across FMCG, Home care, Industrial Cleaning, Personal Care, Textile Speciality Chemicals, Performance Chemicals, the Animal Health and Nutrition and Pet Care businesses. The Company has an extensive and a dedicated network of distributors spread all over India.

For more information, please visit www.rossari.com OR contact:

Ketan Sablok
Rossari Biotech Limited
Tel: +91 22 6123 3800
Email: ketan.sablok@rossari.com

Anoop Poojari / Mitesh Jain
CDR India
Tel: +91 98330 90434 / 96194 44691
Email:anoop@cdr-india.com / mitesh@cdr-india.com

DISCLAIMER:

Certain statements and opinions with respect to the anticipated future performance of Rossari Biotech Limited in the press release ("forward-looking statements"), which reflect various assumptions concerning the strategies, objectives and anticipated results may or may not prove to be correct. Such forward-looking statements involve a number of risks, uncertainties and assumptions which could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These include, among other factors, changes in economic, political, regulatory, business or other market conditions. Such forward-looking statements only speak as at the date the press release is provided to the recipient and Rossari Biotech Limited is not under any obligation to update or revise such forward-looking statements to reflect new events or circumstances. No representation or warranty (whether express or implied) is given in respect of any information in this press release or that this press release is suitable for the recipient's purposes. The delivery of this press release does not imply that the information herein is correct as at any time subsequent to the date hereof and Rossari Biotech Limited has no obligation whatsoever to update any of the information or the conclusions contained herein or to correct any inaccuracies which may become apparent subsequent to the date hereof.